Aims to Submit a Phase 3 IND to the U.S. FDA Next Year

GC Biopharma said on November 3 that it had been selected as a company eligible for support from the National Growth Fund on October 29 and secured a total of KRW 170 billion to develop subcutaneous immunoglobulin (SCIG) for the U.S. market.


The National Growth Fund is a public-private financial program established to foster advanced strategic industries, including biotechnology, artificial intelligence (AI), semiconductors, and secondary batteries.


GC Biopharma headquarters in Yongin, Gyeonggi Province.

GC Biopharma headquarters in Yongin, Gyeonggi Province.

View original image

The company plans to use the funding for Phase 3 clinical trials of 20% SCIG and investment in production facilities, accelerating development. It aims to submit an investigational new drug (IND) application for a Phase 3 clinical trial to the U.S. Food and Drug Administration (FDA) in 2027.


In 2023, GC Biopharma became the first company in South Korea to receive FDA approval for a domestically developed immunoglobulin product, ALYGLO. It went on to achieve exports of more than $100 million in 2025. The company plans to launch new products through infrastructure investment and the rapid advancement of clinical trials, and quickly expand its market share alongside ALYGLO in the U.S. immunoglobulin market, valued at approximately KRW 20 trillion (about $14.4 billion).



GC Biopharma CEO Huh Eun-cheol said, "With 20% SCIG joining ALYGLO, we will complete an immunoglobulin portfolio spanning both intravenous and subcutaneous injections."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing